News for AbCellera Biologics Inc. (ABCL)

U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Monday. Shares of Galaxy Digital GLXY rose sharply during Monday's session after...

Summary AbCellera Biologics Inc (ABCL), a leader in antibody medicine discovery and development, has announced that it will release its second quarter 2025 fina

[url="]AbCellera[/url] (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call

AbCellera Biologics Inc. (ABCL) to release Q2 2025 financial results on August 7, 2025. The company will hold an earnings conference call at 2:00 p.m. P

On July 7, 2025, Leerink Partners has initiated coverage on AbCellera Biologics (ABCL), a biotechnology company, with an "Outperform" rating. Analyst Faisal Khu

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 13 Stocks Under $5 With High Upside Potential. On May 16, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), lowering the price target to $10 from $28. The firm released its updated outlook on the company after the latter released its fiscal […]

On July 1, Ralph Schlosstein, Evercore chairman emeritus and BlackRock co-founder, appeared on CNBC's 'Closing Bell Overtime' to discuss his outlook for markets heading into the second half of 2025.

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential. Earlier in May, AbCellera Biologics announced that the US Court of Appeals for the Federal Circuit/CAFC issued a Rule 36 Order, which affirmed the validity of its US Patent No. 10,087,408 (“the ‘408 Patent”). The patent specifically covers microfluidic devices […]

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio’s Substack. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc. (ABCL)’s share was trading at $2.14 as of 2nd June. ABCL’s trailing P/E was 19.92 according to Yahoo Finance. Abcellera is approaching a potential inflection point […]

Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against atopic dermatitis (AD).

[url="]AbCellera[/url] (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application

AbCellera (ABCL) has received authorization from Health Canada for a Phase 1 clinical trial of ABCL575. The trial is set to begin in Q3 2025, focusing o

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potential over the next 12 months. AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody […]

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article.

AbCellera (ABCL) has secured a significant legal win as the United States Court of Appeals for the Federal Circuit upheld the validity of its U.S. Patent No. 10

AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of val

[url="]AbCellera[/url] (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermato

AbCellera (ABCL) showcases promising preclinical data for ABCL575 at the 2025 SID Annual Meeting. ABCL575 demonstrates potent inhibition

Stifel has revised its price target for AbCellera (ABCL), reducing it from $10 to $8 while maintaining a Buy rating. The adjustment comes as the company prepare